Novo Nordisk has unveiled promising results from its PIONEER TEENS trial, indicating that oral semaglutide could become the first oral GLP-1 receptor agonist approved for managing type 2 diabetes in adolescents aged 10-17. The study showed significant blood sugar reduction and a favorable safety profile, addressing a critical unmet medical need amidst rising rates of youth-onset type 2 diabetes globally.

Medpace Holdings (MEDP) shares experienced a significant drop on Thursday after the company's first-quarter bookings fell short of analyst expectations. Despite reporting an otherwise strong financial performance and reaffirming its full-year guidance, the contract research organization (CRO) recorded a book-to-bill ratio of 0.88x, missing Street forecasts ranging from 0.98x to 1.04x. This unexpected bookings miss sent MEDP stock to a nine-month low.

Oklo's stock experienced a significant surge, primarily driven by its new collaboration with Nvidia and Los Alamos National Laboratory to advance nuclear energy solutions for AI infrastructure. This partnership, alongside a bullish 'buy' rating and a $96 price target from HSBC, signals strong market confidence in the company's future in the advanced nuclear energy sector. The company's innovative approach to AI-powered nuclear research positions it as a key player in sustainable energy for the burgeoning AI industry.

Knight-Swift Transportation is forecasting significant increases in contractual rates for the current and upcoming bidding periods, driven by a tightening freight market. Regulatory pressures and rising fuel costs are reducing available capacity, prompting shippers to secure peak-season transport early. Despite a recent net loss, the company expects improved earnings and operational efficiency across its truckload, LTL, and brokerage segments, signaling a potential market turnaround.

Lockheed Martin's stock fell by 4.7% after its Q1 2026 earnings report revealed a miss on both sales and profit targets. The defense contractor reported $6.44 per share in earnings and $18 billion in sales, below analysts' expectations of $6.74 per share and $18.3 billion. This decline occurred despite increasing demand for its defense products, leading to negative free cash flow for the quarter.